Improved Pharma Expands Its In-House Single Crystal Capabilities
Addition of crystallographer and new instrumentation in support of single crystal structure determination
Improved Pharma has significantly enhanced its in-house capabilities for single crystal structure determination. This exciting development involves the acquisition of a new Rigaku XtaLAB Synergy-i diffractometer, which features advanced technology including a copper X-ray source and a pixel array direct photon counting detector. The new instrument allows the company to analyze crystals as small as 100 microns, ensuring the collection of high-quality data essential for the precise characterization of crystalline materials.
The Importance of Single Crystal Structure Determination
Single crystal structure determination is widely regarded as the gold standard in crystal form identification. This method offers invaluable insights into various aspects of crystal forms, encompassing form purity, density, coformer stoichiometry, unit cell parameters, and absolute configuration. To obtain a deeper understanding of crystalline substances, it is advisable to determine the crystal structure of all forms of interest, with particular focus placed on both anhydrous and hydrated forms.
Meet the Newest Member of the Team
To support its new single crystal capabilities, Improved Pharma has welcomed Jared Smit as part of its talented team of scientists. Jared brings a wealth of experience with a B.S. in Chemistry from Wabash College and a Ph.D. in Inorganic Chemistry from Northwestern University, along with valuable experience gained during his postdoctoral work at the University of Liverpool. Over the course of his impressive 17-year career, he has served as a materials scientist and staff crystallographer at SSCI, where he successfully determined hundreds of crystal structures. His expertise in indexing X-ray powder diffraction patterns has played a crucial role in pharmaceutical solid form development, further solidifying his ability to contribute to Improvements in the field.
About Improved Pharma
Improved Pharma is a research, consulting, and information company with a dedicated mission to enhance pharmaceutical methods, formulations, and processes. The company's service offerings comprise solid-state form studies, formulation design, synchrotron techniques, analytical testing, and expert consulting services aimed at the development and defense of intellectual property matters. Founded in 2006 by Stephen and Sarah Byrn, who also established SSCI, Improved Pharma strives to innovate and improve within the pharmaceutical industry, ensuring the best results for their clients in a highly competitive market.
Frequently Asked Questions
What are the new capabilities Improved Pharma has acquired?
Improved Pharma has recently acquired a Rigaku XtaLAB Synergy-i diffractometer to enhance its in-house single crystal structure determination capabilities.
Why is single crystal structure determination important?
This method provides critical information about crystal quality, including purity, structure, and properties, which are essential for pharmaceutical development.
Who is the newest addition to the Improved Pharma team?
The company has welcomed Jared Smit, a highly experienced crystallographer, to strengthen its capabilities in single crystal analysis.
When was Improved Pharma founded?
Improved Pharma was founded in 2006 by Stephen and Sarah Byrn.
What services does Improved Pharma offer?
Improved Pharma provides a wide range of services including solid-state form studies, formulation design, analytical testing, and consulting for intellectual property development.
